OmniAb (OABI) Cost of Revenue (2025 - 2026)
OmniAb (OABI) reported Cost of Revenue of $15000.0 for Q1 2026, up 400.0% year-over-year from $3000.0 in Q1 2025, and up 66.67% on a QoQ basis from $9000.0 in Q4 2025.
OmniAb (OABI) has 2 years of Cost of Revenue data on file, last reported at $15000.0 in Q1 2026.
- Quarterly Cost of Revenue rose 400.0% year-over-year to $15000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $315000.0 (up 10400.0% YoY) and the FY2025 annual result came in at $303000.0, changed N/A from the prior year.
- Cost of Revenue climbed to $15000.0 in Q1 2026 per OABI's latest filing, from $9000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $262000.0 in Q2 2025 and bottomed at $3000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 262,000.00 |
| Jun 30, 2025 | 262,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |